founded as a spin-off from the Max-Delbrück-Center in Berlin
focus: designing and developing novel therapeutics (stable, synthetic analogs of highly bioactive natural metabolites of omega-3 fatty acids, called epoxyeicosanoids) that can be broadly deployed in inflammatory, cardiovascular, ophthalmology and other disease indications using its proprietary technology and extensive knowledge of omega-3 fatty acid metabolism and biology.
The naturally occurring, but metabolically unstable epoxyeicosanoids have the ability to activate anti-inflammatory, anti-arrhythmic and cardioprotective pathways in cells, making them an attractive target for therapies directed towards a number of diseases including cardiovascular diseases, bronchial disorders, fatty liver disease and multiple eye disorders.
The pipeline of small molecules are orally available and have shown significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts.
Phase I clinical trial has been completed and revealed an excellent safety and tolerability profile for OMEICOS' lead candidate OMT-28.